GAITHERSBURG, Md.--(BUSINESS WIRE)--Calibrant Biosystems, a leader in the field of proteomics-based drug and biomarker discovery and development, today announced the appointments of James Hawkins, PhD, MBA, Bethany Mancilla, MBA, and Douglas Swirsky, CPA, CFA, to its newly-formed Business Advisory Board. Dr. Michael Salgaller, Chief Operating Officer, said “We are excited and honored to have Dr. Hawkins, Ms. Mancilla, and Mr. Swirsky associated with our Company at this important stage in our history. Their stellar talents and successful track records bring a wide range of talents to address the complex, challenging issues facing early-stage biotechnology companies. We look forward to their contributions as our Company continues to grow and develop its Gemini™ proteomics technology and oncology drug and biomarker pipeline.”
